|Bid||19.17 x 800|
|Ask||19.25 x 800|
|Day's Range||19.09 - 19.31|
|52 Week Range||10.90 - 23.05|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.58|
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Don't believe it? Then look at the Codexis, Inc. (NA...
Codexis, Inc. (CDXS), a leading protein engineering company, announces that Jim Lalonde, Ph.D., Senior Vice President of Research and Development, will resign effective May 31, 2019 to pursue other interests. “Jim has played an integral role over many years with the Codexis team refining and applying our CodeEvolver® protein engineering platform. “I am extremely grateful to all of the past and present scientists at Codexis.
Codexis (CDXS) delivered earnings and revenue surprises of 400.00% and -3.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Codexis, Inc.'s (NASDAQ:CDXS): Codexis, Inc. discovers, develops, and sells protein catalysts. The US$1.1b market-cap company announced a latest loss of -US$10.9m on 31 December 2018 for its most recent financialRead More...
REDWOOD CITY, Calif., March 05, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in two upcoming.
Codexis Inc (NASDAQ:CDXS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The small biotech met 2018 guidance and expects another year of growth, but one segment's growth disappoints.
2018 revenues of $61 million include a 50% increase in R&D revenue Introduces 2019 financial guidance Conference call begins at 4:30 pm Eastern time todayAccompanying slide.
Codexis, Inc. (CDXS), a leading protein engineering company, announces the appointment of Laurie Heilmann to Senior Vice President of Business Development and Marketing. Heilmann brings to Codexis more than 30 years of leadership experience across the life sciences industry, and a proven track record of transformative strategies resulting in increased revenue growth, profitability and global brand awareness. Heilmann, reporting to CEO John Nicols, will be responsible for developing the strategies and overseeing the company’s execution to grow global revenues, expand and deepen customer reach, and penetrate a widening set of industrial markets. The company’s global business development and marketing team will report to her.
REDWOOD CITY, Calif., Feb. 19, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year.
Codexis, Inc. (CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder. Nestlé Health Science was granted this option under the Development, Option and Licensing Agreement with Codexis announced in October 2017. CDX-6114 is Codexis’ first internally developed biotherapeutic product candidate.
Codexis, Inc. (CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova® Tablets, a novel, once-daily treatment for overactive bladder. “Our CodeEvolver® technology enabled a computational design strategy to create an enzyme that eliminates several manufacturing steps and performs in a high-pH environment. This proprietary enzyme will now be used to streamline vibegron manufacturing,” said Codexis President and CEO John Nicols. “This agreement with KYORIN is another example of the significant value our technology brings in developing high-performing, value-added enzymes with utility from R&D to commercial-scale manufacturing.
Codexis stock approached a breakout Tuesday after the biotech company struck a deal with Dow Jones giant Merck for its protein-engineering technology. The platform is called CodeEvolver.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
REDWOOD CITY, Calif., Feb. 04, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a.
Every investor in Codexis, Inc. (NASDAQ:CDXS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...